Cyclin D1 anticorps

N° du produit ABIN969007

Détail du produit anti-Cyclin D1 anticorps

Antigène: Cyclin D1 (CCND1)

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Cyclin D1 est non-conjugé

Application: Western Blotting (WB), ELISA

Purification: purified

Immunogène: Purified recombinant fragment of human CCND1 expressed in E. coli.

Clone: 3D8

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1:10000, WB: 1:500 - 1:2000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: 4°C, -20°C for long term storage

Références pour anticorps anti-Cyclin D1 (ABIN969007)

Kurihara, Oda, Ohishi, Kaneki, Kobayashi, Wake, Tsuneyoshi: "Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas." dans: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 23, Issue 2, pp. 225-34, (2010) (PubMed).

Parafioriti, del Bianco, Barisani, Armiraglio, Peretti, Albisetti: "Increased p21 expression in chondrocytes of achondroplasic children independently from the presence of the G380R FGFR3 mutation." dans: Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, Vol. 14, Issue 5, pp. 623-30, (2009) (PubMed).

Détails sur Cyclin D1

Antigène: Cyclin D1 (CCND1)

Autre désignation: CCND1 (CCND1 Produits)

Synonymes: anticorps BCL1, anticorps D11S287E, anticorps PRAD1, anticorps U21B31, anticorps AI327039, anticorps CycD1, anticorps Cyl-1, anticorps bcl-1, anticorps cD1, anticorps cb161, anticorps cycd1, anticorps etID37810.7, anticorps fb52e01, anticorps fc45c08, anticorps fc83a12, anticorps id:ibd1198, anticorps wu:fb52e01, anticorps wu:fc45c08, anticorps wu:fc83a12, anticorps ccnd1b, anticorps prad1, anticorps ccnd1, anticorps ccnd1a, anticorps bcl1, anticorps d11s287e, anticorps u21b31, anticorps CCND1, anticorps cyclin D1, anticorps cyclin D1 S homeolog, anticorps cyclin D1 L homeolog, anticorps CCND1, anticorps Ccnd1, anticorps ccnd1, anticorps ccnd1.S, anticorps ccnd1.L

Sujet:

Description: During each cell cycle cyclins undergo periodic accumulation and destruction. As key regulators of the cell cycle the cyclins control important transitions by acting as regulatory subunits of the Cdks. Early in the G1 phase of the cell cycle, cyclin D1 induction is followed by cyclin E induction. This sequential progression is marked early on in G1 by the activation of Cdk4 and in mid to late G1 by the activation of Cdk2 and the hyperphosphorylation of pRB. The final transition into S phase is thought to be dependent on the increased expression and association of cyclin E and Cdk2. In a recent study, Cyclin D1 regulates cellular metabolism, fat cell differentiation and cellular migration. Cyclin D1 is also involved in development and cancer. Cyclin D1 has also been linked to the development and progression of several cancers including breast, bladder, esophagus, and lung.

Aliases: BCL1, PRAD1, U21B31, D11S287E, CCND1

Poids moléculaire: 33.7 kDa

ID gène: 595

HGNC: 595

Pathways: Signalisation PI3K-Akt, Cycle Cellulaire, Mitotic G1-G1/S Phases, ER-Nucleus Signaling